Pneumonia: a common threat
with serious consequences

A leading cause of
infection-related death in the US1

The need for new antibiotics

~5 mm pneumonia cases annually

~5 mm

~5 mm pneumonia cases annually—

and incidence is expected to rise2,3

S. pneumoniae causes about 36% of all pneumonia cases classified as CABP

S. pneumoniae causes about 36% of all
pneumonia cases classified as CABP4

60% of pneumonia cases are treated in the hospital

Driving up hospitalizations

60% of pneumonia cases are treated in the hospital5

The CDC has deemed drug-resistant S. pneumoniae a particularly concerning public health threat6,7

Resistance patterns can vary by geography, as seen in this example8

Drug-resistant pathogens will undermine the ability to fight infectious diseases—such as pneumonia—as antibiotics become less effective.6 In the absence of culture and susceptibility data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.9

Distribution of azithromycin, penicillin, and tetracycline resistance for S. pneumoniae*,8
Azithromycin
Resistance
Penicillin
Resistance
Tetracycline
Resistance
Pacific 28.8% 26.8% 12.8%
Mountain 23.8% 29.3% 17.5%
West North Central 52.4% 36.1% 18.0%
West South Central 59.1% 56.3% 23.8%
East North Central 44.2% 35.5% 17.4%
East South Central 52.2% 42.2% 28.2%
Mid-Atlantic 40.2% 36.9% 21.4%
South Atlantic 47.0% 42.4% 17.1%
New England 44.7% 28.8% 28.0%

Data presented are from 2010 to 2019 (tetracycline data are from 2015-2019). Dataset provided by JMI Labs and the SENTRY Antimicrobial Surveillance Program, available at sentry-mvp.jmilabs.com. Accessed December 3, 2019. Resistance percentages also include the indeterminate category.

In vitro data are based on Clinical and Laboratory Standards Institute (CLSI) 2019 susceptibility breakpoints. Streptococcus pneumoniae isolates are from bloodstream and community-acquired respiratory tract infections.8

CLSI breakpoint (penicillin = oral, non-meningitis)

New antibiotics are valuable to effective antibiotic stewardship

For nearly 20 years, there has been no novel class approved for the treatment of CABP—yet new antibiotics are valuable for effective antibiotic stewardship10-12

IDSA/SHEA antibiotic stewardship guidelines for antibiotic use and sustainability include but are not limited to10,13:

Transitioning early from IV to oral

Transitioning early
from IV to oral

administration to help shorten length of stay

shortest effective duration

Using antibiotic therapy for the

shortest
effective duration

new antibiotic classes

Developing systemic drugs in

new antibiotic classes

to address resistance

IDSA=Infectious Diseases Society of America; MIC=minimum inhibitory concentration; SHEA=Society of Healthcare Epidemiology in America.
CABP is a designation by the FDA to refer specifically to CAP patients with bacterial pneumonia.